Overview
Ladder Bio Inc., formerly thirdlaw molecular, secured $5.5 million in a seed financing round led by Medical Excellence Capital, with participation from Hatch Biofund. The company develops spiroligomer therapeutics aimed at addressing "undruggable" targets, combining the benefits of biologics and small molecules.
Products
Loading...
Recent Deals
Investors: Medical Excellence Capital, Hatch Biofund
Ladder Bio Inc., formerly thirdlaw molecular, secured $5.5 million in a seed financing round led by Medical Excellence Capital, with participation from Hatch Biofund. The company develops spiroligomer therapeutics aimed at addressing "undruggable" targets, combining the benefits of biologics and small molecules.